Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance

by Zacks Equity Research

PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.

DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.

Thermo Fisher (TMO) Completes Acquisition of Leading CRO

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.

Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test

by Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

by Zacks Equity Research

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm

by Zacks Equity Research

BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.

NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business

by Zacks Equity Research

NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of the da Vince Surgical System. Higher production costs are a woe.

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

by Zacks Equity Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

OPKO Health (OPK) Receives FDA Nod for the 4Kscore Test

by Zacks Equity Research

OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.

Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable

by Zacks Equity Research

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Integer Holdings (ITGR) Buys Oscor, Boosts Global Footprint

by Zacks Equity Research

Integer Holdings' (ITGR) acquisition of Oscor is likely to bolster its already solid global presence.

Is Invesco Dynamic Large Cap Growth ETF (PWB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWB

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.

Here's Why You Should Retain Abiomed (ABMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.

BD's (BDX) Buyout of Venclose to Improve Patient Outcome

by Zacks Equity Research

BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.

Avanos Medical's (AVNS) App to Support Pain Management Process

by Zacks Equity Research

Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.

Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools

by Zacks Equity Research

Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.